Rapid Nexus Clinches 1st Place at PitchForce

Dr. Margaret Kalmeta was handpicked by a panel of seasoned investors as the 1st-place winner at PitchForce, where she delivered a compelling 4-minute pitch on Rapid Nexus Nanotech Wound Solutions, Inc. Her presentation highlighted the company’s cutting-edge regenerative wound care technology and its potential to transform patient outcomes. This recognition underscores the team’s dedication and innovation, as well as Rapid Nexus’s growing visibility in the medical technology community. Dr. Kalmeta expressed gratitude for the opportunity to share the company’s mission with a broad audience and for the confidence shown by the investors.  

Rapid Nexus Presents Hemastyl™ at Burn and Reconstructive Centers of America

Dr. Margaret Kalmeta had the privilege of serving as Keynote Speaker at the Burn and Reconstructive Centers of America, presenting Rapid Nexus’s innovative Peri-wound treatment, Hemastyl™. The presentation sparked significant interest, leading to an engaging Q&A session covering clinical insights and practical applications. Key highlights from the discussion included: Treatment Duration: One case of a necrotic, infected diabetic leg ulcer scheduled for amputation was successfully treated over 39 weeks during a feasibility study. Rapid Nexus notes that ongoing clinical trials are progressing faster. Clinical Collaboration: Dedicated doctors participated in the studies, including transporting patients from the ER to the treatment site. Target Patients: Hemastyl™ is intended for diabetic patients with failed conservative treatments, focusing on Wagner 2–3 cases and exploring Wagner 4 cases. The therapy has demonstrated a reduction in bacterial counts and shows promise for recalcitrant patients. Antimicrobial Effects: The wound dressing contains three major antimicrobials. Infrared light is used primarily to accelerate healing, with minor antimicrobial contribution. This session reinforced Rapid Nexus’s commitment to advancing regenerative wound care and its potential to prevent amputations and improve patient outcomes.

Preventing Amputations: Rapid Nexus Clinical Results

At LSI, Dr. Kalmeta shares early results from Rapid Nexus’s regenerative wound care technology, highlighting that 17 amputations were prevented and 39 complex wounds were successfully closed by treating tissue surrounding the wound. This demonstrates the potential impact of Rapid Nexus’s platform on diabetic patients at risk for limb loss. Half of diabetic patients who undergo an amputation die within two years. In a recent study, Rapid Nexus Nanotech Wound Solutions, Inc. successfully prevented 17 amputations and closed 39 complex wounds by treating the tissue surrounding the affected area—stopping scheduled amputations before they were needed. This represents just a glimpse of what our regenerative technology can achieve. Watch the rest of the presentation here.